Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
Hologic (HOLX) reported insider activity by its General Counsel. On November 10, 2025, the officer received 17,496 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. Shares were withheld to cover taxes upon RSU settlement: 288 shares at $74.10 on November 7 and 406 shares at $74.60 on November 11. Following these transactions, direct ownership stood at 28,574 shares. This total includes 346 shares acquired through the employee stock purchase plan since the prior report.
Hologic, Inc. announced a governance update related to equity compensation. On November 4, 2025, the company’s Compensation Committee approved a revised form of Restricted Stock Unit (RSU) Award Agreement, adopted for fiscal 2026. The revised agreement is provided as Exhibit 10.1 to the report and incorporated by reference. This is an administrative update to the standard documentation governing future RSU grants and does not disclose financial terms or changes to award amounts.
Hologic (HOLX) reported insider activity by its Chairman, President and CEO. On 11/04/2025, the executive acquired 83,589 shares of common stock designated as performance stock units, for which performance criteria have been satisfied but that remain subject to service-based vesting. Following the transaction, directly owned shares totaled 1,318,213. Indirect holdings were 1,146,829 shares through the MacMillan Family Trust.
The total includes 1,079,673 restricted/performance stock units whose settlement has been deferred under the company’s Deferred Equity Plan. Performance stock units settle one-for-one into common stock.
Hologic, Inc. (HOLX) reported an insider equity change by a company officer (Group President, International). On 11/04/2025, the officer acquired 15,196 shares of common stock, tied to performance stock units where the performance criteria have been met but the award remains subject to service-based vesting. Following this transaction, the officer beneficially owns 119,010 shares, held directly. The filing notes that performance stock units settle into common stock on a one-for-one basis.
Hologic (HOLX) reported an insider equity update. The Chief Financial Officer filed a Form 4 showing an acquisition of 17,095 performance stock units on 11/04/2025 (transaction code A). These units have met performance criteria and remain subject to service-based vesting, and are settled one-for-one in common stock. Following the transaction, the officer beneficially owned 119,203 shares, which includes 41,121 RSUs/PSUs with settlement deferred under the company’s Deferred Equity Plan. Ownership is listed as direct.
Hologic, Inc. (HOLX) Chief Operating Officer reported an equity acquisition on 11/04/2025 via Form 4. The filing shows 9,116 shares of common stock acquired (Code A), which the footnotes describe as performance stock units for which performance criteria have been satisfied but that remain subject to service-based vesting. These units settle into common stock on a one-for-one basis.
Following the reported transaction, the executive beneficially owned 37,474 shares, held directly. The filing also notes that this total includes 401 shares acquired through the issuer’s employee stock purchase plan since the executive’s most recent report.
Hologic (HOLX) reported an insider equity change by its officer, the President, Breast & Skeletal. On 11/04/2025, the reporting person acquired 2,278 shares of common stock (code A). The filing notes these relate to performance stock units for which performance criteria were met but that remain subject to service-based vesting, and such units are settled one-for-one in common stock.
Following the reported transaction, the reporting person beneficially owned 9,681 shares directly. This figure includes 346 shares acquired under the employee stock purchase plan since the prior report and 2,327 restricted stock units whose settlement has been deferred under the Issuer’s Deferred Equity Plan.
Hologic (HOLX) reported an insider equity change: the company’s Principal Accounting Officer acquired 2,656 shares of common stock on 11/04/2025, reported on Form 4. Following this transaction, the reporting person beneficially owns 14,283 shares.
The filing notes these were performance stock units for which performance criteria were met, and they remain subject to service-based vesting. The units are settled in common stock on a one-for-one basis. The ownership total includes 377 shares acquired through the company’s employee stock purchase plan.
Hologic, Inc. (HOLX) furnished its Q4 financial results via a press release for the quarter ended September 27, 2025. The release was provided under Item 2.02 and is attached as Exhibit 99.1. The company noted that this information is furnished, not filed, and included standard cautionary language regarding forward‑looking statements.
Hologic also referenced a proposed acquisition by affiliates of Blackstone Inc. and TPG Capital. The company plans to file and mail a definitive Proxy Statement to stockholders in connection with the proposed transaction and urged investors to review those materials when available at the SEC’s website and Hologic’s investor relations page.
Hologic (HOLX) reported an insider transaction by a company director on 10/20/2025. The director exercised 7,402 non-qualified stock options at $36.04 per share (code M) and on the same day sold 7,402 shares at an average price of $73.07 (code S). Following these transactions, the director beneficially owns 47,336 shares, held directly. The activity was carried out under a Rule 10b5-1 trading plan adopted on February 19, 2025. The exercised option was set to expire on March 2, 2026.